HC Wainwright restated their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV – Free Report) in a research note published on Tuesday morning, Benzinga reports. They currently have a $7.00 price objective on the stock.
Enlivex Therapeutics Price Performance
NASDAQ:ENLV opened at $1.44 on Tuesday. The company has a market cap of $26.74 million, a price-to-earnings ratio of -0.92 and a beta of 1.02. The stock’s 50 day simple moving average is $3.15 and its two-hundred day simple moving average is $2.52. Enlivex Therapeutics has a 1 year low of $1.15 and a 1 year high of $4.59.
Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) last released its earnings results on Friday, March 29th. The company reported ($0.48) earnings per share for the quarter. As a group, analysts anticipate that Enlivex Therapeutics will post -0.86 EPS for the current year.
About Enlivex Therapeutics
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.
Read More
- Five stocks we like better than Enlivex Therapeutics
- Profitably Trade Stocks at 52-Week Highs
- 3 Stocks Leading the U.S. Agriculture Comeback
- Investing in Travel Stocks Benefits
- How to Use Put Debit Spreads to Profit From Falling Stocks
- 3 Warren Buffett Stocks to Buy Now
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
